PF-05082566: Phase I data

Data from 27 evaluable cancer patients in the first part of a 2-part, open-label, dose-escalation, U.S. and French Phase I trial showed that once-monthly doses of 0.006-0.3 mg/kg IV PF-05082566 were well tolerated and led to 6 cases of stable disease. There was 1 case of grade 3 elevation in alkaline phosphatase levels at the 0.06 mg/kg PF-05082566 dose. No other significant elevations in liver enzymes or DLTs were reported. The first part of the trial enrolled patients with advanced cancer for which no curative therapy is available. The second part of the trial will evaluate PF-05082566 in combination with Rituxan rituximab in patients with relapsed or refractory CD20-positive non-Hodgkin's lymphoma (NHL) for which no curative therapy is available. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...